Filtered By:
Condition: Pain
Cancer: Oral Cancer
Management: Hospitals
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 7 results found since Jan 2013.
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
A Serious Diagnosis Lacking Common Symptoms
BY JENNIFER TUONG; IVAN KHARCHENKO; JEAN LUC AGARD; & AHMED RAZIUDDIN, MDA 65-year-old man who had HIV well-controlled with highly active antiretroviral therapy, hypertension, sciatica, and restless leg syndrome presented to the emergency department with left leg pain. He also had had chemotherapy and radiation for anal cancer. The patient said the pain had started 45 minutes earlier when he was sitting on the toilet.He described the pain as sore in quality and 10/10 on the pain scale. He reported that it had started in his lower back and radiated to his left leg. He said he had had no trauma or weakness to the regi...
Source: The Case Files - May 28, 2019 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
5 Scary Symptoms That Are Usually Harmless
SPECIAL FROM Next Avenue
By Linda Melone
After 50, aches, pains and the occasional muscle twinge become a fact of life. But some symptoms that may seem frightening or serious turn out to be far less than they appear.
While you should always see a doctor if you experience something out of the ordinary, these signs generally are more smoke than fire:
A Bloody Nose
Nosebleeds can be particularly frightening due to the suddenness in which they occur and the sometimes large amount of blood involved.
“People worry that it’s internal bleeding, but almost every time it’s not,” says Dr. Carlo Reyes, emergency room...
Source: Healthy Living - The Huffington Post - February 5, 2015 Category: Consumer Health News Source Type: news
A father ’s hope for his son’s life
Juan and Fredy in 2017.
Juan was looking forward to having his son, Fredy, 14, finally come home to live with him. The teenager had been living under the care of his grandmother since he was a toddler.
But on that long-awaited homecoming day, Juan was quickly jarred from feeling great joy to grave concern.
“When I saw his face, one side looked very different from the other and his lip was swollen,” says Juan. “He admitted right away that his face had been hurting.”
Juan remembered that the last time he’d seen his son — more than one year ago — Fredy’s face had looked slightly different then too. But whateve...
Source: Thrive, Children's Hospital Boston - April 12, 2017 Category: Pediatrics Authors: Kat J. McAlpine Tags: Diseases & Conditions Our Patients’ Stories Dr. Cameron Trenor Dr. Carolyn Rogers Dr. Darren Orbach Dr. Reza Rahbar Dr. Salim Afshar interventional radiology juvenile nasopharyngeal angiofibroma tumor Source Type: news
Mind the Treatment Gap
getty images/ istock photoBy Vani S. Kulkarni and Raghav GaihaPHILADELPHIA AND NEW DELHI, Apr 14 2017 (IPS)Implementation of the Mental Healthcare Act will require a restructuring of health-care services The Mental Healthcare Bill, 2016, which was passed in the Lok Sabha on March 27, 2017, has been hailed as a momentous reform. According to the Bill, every person will have the right to access mental health care operated or funded by the government; good quality and affordable health care; equality of treatment and protection from inhuman practices; access to legal services; and right to complain against coercion and cruelt...
Source: IPS Inter Press Service - Health - April 14, 2017 Category: Global & Universal Authors: Vani Kulkarni and Raghav Gaiha Tags: Asia-Pacific Development & Aid Gender Gender Violence Headlines Health Human Rights Women's Health Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
